Moving Stocks: Atwood Oceanics, Inc. (NYSE:ATW), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Penn West Petroleum Ltd. (NYSE:PWE), Neurocrine Biosciences Inc. (NASDAQ:NBIX),

Atwood Oceanics, Inc. (NYSE:ATW) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday, AnalystRatings.Net reports. The brokerage presently has a $7.00 target price on the stock. Zacks Investment Research‘s price objective suggests a potential upside of 12.72% from the company’s current price.

Atwood Oceanics, Inc. (NYSE:ATW) belongs to Basic Materials sector. Its net profit margin is 31.50% and weekly performance is -3.12%. On last trading day company shares ended up at $6.21. Atwood Oceanics, Inc. (NYSE:ATW) distance from 50-day simple moving average (SMA50) is -23.50%.

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) said that, its new CEO hinted strongly at cost-cutting, potential mergers or partnerships, and drug price increases as potential ways to “increase shareholder value” in the coming year.

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) shares moved up 5.36% in last trading session and ended the day at $5.11. ARIA Gross Margin is 98.30% and its return on assets is -30.80%. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) quarterly performance is -20.40%.

On 16 February, Penn West Petroleum Ltd. (NYSE:PWE) has reached agreements to settle a bevy of class-action lawsuits stemming from accounting. The settlement in the Canadian and U.S. cases will be fully funded by the company’s insurance, meaning its cash resources and financial position won’t take a hit.

Penn West Petroleum Ltd. (NYSE:PWE) belongs to Basic Materials sector. Its weekly performance is -1.72%. On last trading day company shares ended up at $0.95. Penn West Petroleum Ltd. (NYSE:PWE) distance from 50-day simple moving average (SMA50) is 19.97%.

On 11 February, Neurocrine Biosciences Inc. (NASDAQ:NBIX) announced its financial results for the quarter and year ended December 31, 2015.For the fourth quarter of 2015, the Company reported a net loss of $29.3 million, or $0.34 loss per share, compared to a net loss of$19.4 million, or $0.26 loss per share for the same period in 2014. For the year ended December 31, 2015, the Company reported a net loss of $88.9 million, or $1.05 loss per share, as compared to a net loss of $60.5 million, or $0.81 loss per share for 2014

Neurocrine Biosciences Inc. (NASDAQ:NBIX) ended the last trading day at $37.05. Company weekly volatility is calculated as 6.08% and price to cash ratio as 8.45. Neurocrine Biosciences Inc. (NASDAQ:NBIX) showed a weekly performance of -2.86%.

Pengrowth Energy Corporation (NYSE:PGH) announce its financial and operating results for the fourth quarter and the full year 2015, as well as 2015 year end reserves results. Pengrowth was able to realize $327 million of hedging gains in 2015 and delivered full year funds flow of $459.3 million and cash flow after capital expenditures of $275.5 million.

Pengrowth Energy Corporation (NYSE:PGH) shares moved up 4.26% in last trading session and ended the day at $0.75. PGH Gross Margin is 74.40% and its return on assets is -19.20%. Pengrowth Energy Corporation (NYSE:PGH) quarterly performance is -7.58%.

Leave a Reply

Your email address will not be published. Required fields are marked *